Comparative Pharmacology
Head-to-head clinical analysis: GLYRX PF versus TOLTERODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYRX PF versus TOLTERODINE.
GLYRX-PF vs TOLTERODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a quaternary ammonium anticholinergic that inhibits muscarinic acetylcholine receptors, thereby reducing salivary secretion and blocking vagally mediated bronchoconstriction.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with selectivity for the M3 receptor subtype involved in detrusor muscle contraction, reducing bladder smooth muscle contractility and increasing bladder capacity.
Intravenous: 1 mg/kg of ideal body weight for 2 minutes, repeated in 2 hours if required; thereafter every 4 hours as needed.
2 mg PO twice daily; may reduce to 1 mg twice daily if tolerated.
None Documented
None Documented
Clinical Note
moderateTolterodine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Clotrimazole
Terminal elimination half-life of 4-6 hours; prolonged to 10-12 hours in renal impairment.
Terminal elimination half-life is 2-4 hours in extensive CYP2D6 metabolizers; increased to 4-10 hours in poor metabolizers or with CYP3A4 inhibitors.
Primarily renal excretion of unchanged drug (70-80%) and metabolites; minor biliary excretion (<10%).
Primarily hepatic metabolism via CYP2D6 and CYP3A4; renal excretion accounts for <5% of unchanged drug; ~80% excreted in urine as metabolites, ~20% in feces.
Category C
Category A/B
Anticholinergic
Anticholinergic
"The metabolism of Clotrimazole can be decreased when combined with Tolterodine."